BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,356 | +169.0% | 191,527 | +167.8% | 0.12% | +132.0% |
Q2 2023 | $504 | -60.7% | 71,532 | -53.5% | 0.05% | -60.6% |
Q1 2023 | $1,282 | -99.5% | 153,718 | +703.9% | 0.13% | +296.9% |
Q3 2022 | $241,000 | -59.2% | 19,121 | -53.5% | 0.03% | -46.7% |
Q3 2021 | $591,000 | -27.6% | 41,116 | -48.7% | 0.06% | -55.6% |
Q1 2021 | $816,000 | +946.2% | 80,197 | +663.8% | 0.14% | +938.5% |
Q4 2020 | $78,000 | -58.7% | 10,500 | -73.5% | 0.01% | -87.6% |
Q2 2020 | $189,000 | -31.8% | 39,599 | -71.4% | 0.10% | +52.2% |
Q1 2020 | $277,000 | -15.8% | 138,664 | +243.4% | 0.07% | +109.1% |
Q1 2019 | $329,000 | +376.8% | 40,383 | +208.6% | 0.03% | +560.0% |
Q3 2017 | $69,000 | -84.0% | 13,086 | -63.0% | 0.01% | -83.3% |
Q4 2014 | $430,000 | -19.6% | 35,350 | -35.3% | 0.03% | +7.1% |
Q3 2014 | $535,000 | – | 54,674 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |